参考文献/References:
[1] Kario K,Kim BK,Aoki J,et al. Renal denervation in Asia:consensus statement of the Asia Renal Denervation Consortium[J]. Hypertension,2020,75(3):590-602.
[2] Vongpatanasin W,Addo T. The next chapter of renal denervation after US Food and Drug Administration Approval[J]. Circulation,2024,149(10):760-763.
[3] Fengler K,Rommel KP,Blazek S,et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)[J]. Circulation,2019,139(5):590-600.
[4] Sakakura K,Roth A,Ladich E,et al. Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound:a next-generation approach for treating sympathetic overactivity[J]. EuroIntervention,2015,10(10):1230-1238.
[5] Sakakura K,Ladich E,Cheng Q,et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man[J]. J Am Coll Cardiol,2014,64(7):635-643.
[6] Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension[J]. Annu Rev Med,2013,64:233-247.
[7] Mancia G,Kreutz R,Brunstr?m M,et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension:Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens,2023,41(12):1874-2071.
[8] Yang Y,Reincke M,Williams TA. Prevalence,diagnosis and outcomes of treatment for primary aldosteronism[J]. Best Pract Res Clin Endocrinol Metab,2020,34(2):101365.
[9] Zhang Z,Zhang X,Ye R,et al. Patient preference for renal denervation therapy in hypertension:a cross-sectional survey in Chengdu,China[J]. Hypertens Res,2022,45(6):954-961.
[10] Dorenkamp M,Bonaventura K,Leber AW,et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension[J]. Eur Heart J,2013,34(6):451-461.
[11] Tsioufis C,Ziakas A,Dimitriadis K,et al. Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension:data from the Greek Renal Denervation Registry[J]. Clin Res Cardiol,2017,106(5):322-330.
[12] Fengler K,Rommel KP,Blazek S,et al. Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation[J]. J Hypertens,2018,36(7):1578-1584.
[13] Reshetnik A,Gohlisch C,Scheurig-Münkler C,et al. Predictors for success in renal denervation-a single centre retrospective analysis[J]. Sci Rep,2018,8(1):15505.
[14] B?hm M,Tsioufis K,Kandzari DE,et al. Effect of heart rate on the outcome of renal denervation in patients with uncontrolled hypertension[J]. J Am Coll Cardiol,2021,78(10):1028-1038.
[15] Fengler K,Rommel KP,Kriese W,et al. Assessment of arterial stiffness to predict blood pressure response to renal sympathetic denervation[J]. EuroIntervention,2022,18(8):e686-e694.
[16] Sata Y,Hering D,Head GA,et al. Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation[J]. J Hypertens,2018,36(6):1414-1422.
[17] Mahfoud F,Townsend RR,Kandzari DE,et al. Changes in plasma renin activity after renal artery sympathetic denervation[J]. J Am Coll Cardiol,2021,77(23):2909-2919.
[18] Lambert GW,Straznicky NE,Lambert EA,et al. Sympathetic nervous activation in obesity and the metabolic syndrome--causes,consequences and therapeutic implications[J]. Pharmacol Ther,2010,126(2):159-172.
[19] Lv R,Liu X,Zhang Y,et al. Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome[J]. Signal Transduct Target T her,2023,8(1):218.
[20] Simpson LL,Stembridge M,Siebenmann C,et al. Mechanisms underpinning sympathoexcitation in hypoxia[J]. J Physiol,2024.DOI:10.1113/JP284579.
[21] Esler M,Lambert G,Esler D,et al. Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension[J]. J H ypertens,2020,38(8):1488-1495.
[22] Nair GKK,Massé S,Asta J,et al. The need for and the challenges of measuring renal sympathetic nerve activity[J]. Heart Rhythm,2016,13(5):1166-1171.
[23] van Amsterdam WA,Blankestijn PJ,Goldschmeding R,et al. The morphological substrate for Renal Denervation:nerve distribution patterns and parasympathetic nerves. A post-mortem histological study[J]. Ann A nat,2016,204:71-79.
[24] Zhou H,Li Y,Xu Y,et al. Mapping renal innervations by renal nerve stimulation and characterizations of blood pressure response patterns[J]. J C ardiovasc T ransl R es,2022,15(1):29-37.
[25] Cheng X,Zhang Y,Chen R,et al. Anatomical evidence for parasympathetic innervation of the renal vasculature and pelvis[J]. J Am Soc Nephrol,2022,33(12):2194-2210.
[26] Wang J,Sun N,Ge J,et al. Rationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial (SMART) for the treatment of hypertension:a prospective,multicenter,single-blind,randomized and sham procedure-controlled study[J]. J C ardiovasc T ransl R es,2023,16(2):358-370.
[27] Liu H,Li Y,Zhou H,et al. Renal nerve stimulation identifies renal innervation and optimizes the strategy for renal denervation in canine[J]. J T ransl M ed,2023,21(1):100.
[28] Wang J,Yin Y,Lu C,et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART):6-month follow-up of a randomised,controlled trial[J]. EClinicalMedicine,2024,72:102626.
[29] Hoogerwaard AF,de Jong MR,Elvan A. Renal nerve stimulation as procedural end point for renal sympathetic denervation[J]. Curr H ypertens R ep,2018,20(3):24.
[30] de Jong MR,Adiyaman A,Gal P,et al. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation[J]. Hypertension,2016,68(3):707-714.
[31] Huang HC,Pan HY,Wang TD. Renal nerve stimulation predicted blood pressure-lowering responses to percutaneous renal denervation[J]. Circ Cardiovasc Interv,2023,16(2):e012779.
[32] Wang L,Li C,Li Z,et al. Ten-year follow-up of very-high risk hypertensive patients undergoing renal sympathetic denervation[J]. J H ypertens,2024,42(5):801-808.
[33] Schirmer SH,Sayed MM,Reil JC,et al. Improvements in left ventricular hypertrophy and diastolic function following renal?denervation:effects beyond blood pressure and heart rate reduction[J]. J Am Coll Cardiol,2014,63(18):1916-1923.
[34] Mahfoud F,Urban D,Teller D,et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension:data from a multi-centre cardiovascular magnetic resonance imaging trial[J]. Eur H eart J,2014,35(33):2224-31b.
[35] Sousa H,Branco P,de Sousa Almeida M,et al. Changes in albumin-to-creatinine ratio at 12-month follow-up in patients undergoing renal denervation[J]. Rev P ort C ardiol,2017,36(5):343-351.
[36] Kordalis A,Tsiachris D,Pietri P,et al. Regression of organ damage following renal denervation in resistant hypertension:a meta-analysis[J]. J H ypertens,2018,36(8):1614-1621.
[37] Goyal A,Jain H,Verma A,et al. The role of renal denervation in cardiology and beyond:An updated comprehensive review and future directives[J]. Curr P robl C ardiol,2024,49(2):102196.
[38] Donazzan L,Mahfoud F,Ewen S,et al. Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension[J]. Clin R es C ardiol,2016,105(4):364-371.
[39] Berukstis A,Vajauskas D,Gargalskaite U,et al. Impact of renal sympathetic denervation on cardiac sympathetic nerve activity evaluated by cardiac MIBG imaging[J]. EuroIntervention,2016,11(9):1070-1076.
[40] Selejan SR,Linz D,Mauz M,et al. Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome[J]. Basic Res C ardiol,2022,117(1):36.
[41] Kiuchi MG,Carnagarin R,Schultz C,et al. Update on advanced interventional neuromodulatory approaches to lower blood pressure[J]. Heart,2023,109(23):1734-1740.
[42] Chernin G,Szwarcfiter I,Bausback Y,et al. Renal sympathetic denervation system via intraluminal ultrasonic ablation:therapeutic intravascular ultrasound design and preclinical evaluation[J]. J V asc I nterv R adiol,2017,28(5):740-748.
[43] Kandzari DE,Weber MA,Pathak A,et al. Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications:primary results from the TARGET BP I randomized clinical trial[J]. Circulation,2024,149(24):1875-1884.
[44] Vakhrushev AD,Condori Leandro HI,Goncharova NS,et al. Laser renal denervation:a comprehensive evaluation of microstructural renal artery lesions[J]. Anat R ec(Hoboken),2023,306(9):2378-2387.
[45] Hwang J,Shin H,Jung M,et al. Investigations of laser-assisted renal denervation for treatment of resistant hypertension[J]. Lasers S urg M ed,2024.DOI:10.1002/lsm.23823.
[46] Barbato E,Azizi M,Schmieder RE,et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur H eart J ,2023,44(15):1313-1330.
[47] Cai X,Yang Y,Shen Y,et al. Noninvasive stereotactic radiotherapy for renal denervation in a swine model[J]. J Am Coll Cardiol,2019,74(13):1697-1709.
[48] Schmieder RE,Ott C,Bramlage P. Non-invasive renal denervation:update on external ultrasound approaches[J]. Curr H ypertens R ep,2016,18(6):48.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]李昱熙 张震 余静 蒋雄京.去肾神经治疗高血压的临床前景和探索方向[J].心血管病学进展,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
LI YuxiZHANG ZhenYU JingJIANG Xiongjing.Future of Renal Denervation on Hypertension Therapy[J].Advances in Cardiovascular Diseases,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
[12]亢园园 罗淞元 许建忠 罗建方 卢成志.当前不同去肾神经术的特点和存在的问题[J].心血管病学进展,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
KANG yuanyuan,LUO Songyuan,XU Jianzhong,et al.The Mechanisms and Future Challenges of Different Renal Denervation Therapy[J].Advances in Cardiovascular Diseases,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
[13]王沛坚 陈威 董徽 马为.中国自主研发RDN器械治疗高血压临床试验数据的特色[J].心血管病学进展,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
WANG Peijian,CHEN Wei,DONG Hui,et al.Characteristics of Clinical Trial Data of RDN Devices Independently Developed in China[J].Advances in Cardiovascular Diseases,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
[14]封欣妤 张冬颖 邹玉宝 冯颖青 程康.如何选择去肾神经术治疗高血压的最适宜人群[J].心血管病学进展,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
FENG Xinyu,ZHANG Dongying,ZOU Yubao,et al.How to Select the Optimal Population for Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
[15]董一飞 张毅 李燕 贾楠.经皮去肾神经术治疗高血压的临床获益：证据和争议[J].心血管病学进展,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]
DONG Yifei,ZHANG Yi,LI Yan,et al.Clinical Benefit of Renal Denervation In the Treatment of Hypertension:Evidence And Controversy[J].Advances in Cardiovascular Diseases,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]